Nrf2 20thin
Recensa 20therapeutics

Recensa Therapeutics, Inc.

Developing a new way to treat psoriasis by targeting oxidative stress

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, US
  • Currency USD
  • Founded June 2016
  • Employees 1
  • Incorporation Type C-corp
  • Website recensatherapeutics.com

Company Summary

Recensa Therapeutics has a novel way to treat inflammation: activate Nrf2, a master controller of the cell's antioxidant response. Supported by the University City Science Center and using Temple University technology, Recensa will be first-to-market with a topical, small molecule pharmaceutical for the six million U.S. patients with mild-to-moderate psoriasis--a group that is highly dissatisfied using older products with many side effects.

Team

  • Matt 20handel  formal
    President

    Mr. Handel, a co-founder of Recensa, is an expert in product development, funding & business development, corporate strategy, and commercialization, both in the U.S. and internationally. He has helped develop and launch multiple products and worked on many licenses and acquisitions. He has worked at Merck and Shire and is a Board Director for PolyAurum LLC. Mr. Handel graduated from Princeton University and received his M.S. from MIT.

  • Fullsizerender
    Scientific Co-Founder

    Dr. Perez is a co-founder of Recensa, the discoverer of the relationship between Nrf2 and psoriasis, and is the inventor of Recensa's underlying technology. He is an assistant professor at the Moulder Center for Drug Discovery at Temple University. Dr. Perez received his M.D. from the Universidad del Norte in Colombia and his M.B.A. from Temple.

Previous Investors

  • Default avatar
    University City Science Center
    Unconfirmed